Wall Street analyst estimates for Twist Bioscience Corporation (TWST): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 2 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 15 |
| Avg rating (1-5) | 0.60 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.44 | ||
| 2026-08-03 | $-0.56 | $-0.51 | -10.6% |
| 2026-05-04 | $-0.71 | $-0.49 | -44.9% |
| 2026-02-02 | $-0.50 | $-0.48 | -4.2% |
| 2025-11-14 | $-0.45 | $-0.50 | +10.0% |
| 2025-08-04 | $-0.47 | $-0.54 | +13.0% |
| 2025-05-05 | $-0.66 | $-0.56 | -17.9% |
| 2025-02-03 | $-0.53 | $-0.62 | +14.5% |
Valuation Ratios
| Price / Book | 26.41 |
| EV / EBITDA | -118.21 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3M | $10.8M | $25.4M | $54.4M | $90.1M | $132.3M | $203.6M | $245.1M | $313.0M | $376.6M |
| Cost of Revenue | $9.4M | $24.0M | $32.2M | $47.4M | $61.4M | $80.6M | $119.3M | $155.4M | $179.6M | $185.6M |
| Gross Profit | -$7.2M | -$13.3M | -$6.8M | $7.0M | $28.7M | $51.7M | $84.2M | $89.7M | $133.3M | $191.0M |
| Research & Development | $18.2M | $19.2M | $20.3M | $35.7M | $43.0M | $69.1M | $120.3M | $106.9M | $90.9M | $80.3M |
| Selling, General & Admin | $18.3M | $26.1M | $43.5M | $80.1M | $103.3M | $135.9M | $212.9M | $189.7M | $218.4M | $247.0M |
| Operating Expenses | $36.5M | $45.2M | $63.8M | $115.8M | $168.8M | $204.4M | $319.0M | $306.9M | $354.2M | $327.3M |
| Operating Income | -$43.7M | -$58.5M | -$70.6M | -$108.8M | -$140.1M | -$152.7M | -$234.8M | -$217.2M | -$220.8M | -$136.3M |
| EBITDA | -$39.1M | -$53.1M | -$64.0M | -$99.8M | -$132.1M | -$143.9M | -$211.7M | -$174.2M | -$176.7M | -$52.1M |
| Interest Expense | $746,000 | $905,000 | $1.3M | $1.3M | $787,000 | $367,000 | $80,000 | $5,000 | $29,000 | 0 |
| Pre-tax Income | -$44.1M | -$59.0M | -$71.0M | -$107.4M | -$139.5M | -$154.0M | -$228.3M | -$203.5M | -$208.2M | -$77.0M |
| Income Tax | 0 | $280,000 | $242,000 | $292,000 | $382,000 | -$1.9M | -$10.4M | $1.2M | $560,000 | $719,000 |
| Net Income | -$44.1M | -$59.3M | -$71.2M | -$107.7M | -$139.9M | -$152.1M | -$217.9M | -$204.6M | -$208.7M | -$77.7M |
| EPS | $-2.35 | $-3.16 | $-2.68 | $-3.92 | $-3.57 | $-3.15 | $-4.04 | $-3.60 | $-3.60 | $-1.30 |
| EPS (Diluted) | $-2.35 | $-3.16 | $-2.68 | $-3.92 | $-3.57 | $-3.15 | $-4.04 | $-3.60 | $-3.60 | $-1.30 |
| Shares Outstanding (Diluted) | $18.8M | $18.8M | $26.6M | $27.5M | $39.2M | $48.3M | $53.9M | $56.9M | $58.0M | $59.8M |
Price
| Price | $205.00 |
| Market Cap | $12.8B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BGM · CLOV · EWTX · GPCR · GRDN · MESO · PRCT
Explore sector: Healthcare · Biotechnology
More sections of TWST: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks